Applied Therapeutics Inc (NASDAQ: APLT)’s stock price has dropped by -2.91 in relation to previous closing price of 5.50. Nevertheless, the company has seen a loss of -9.80% in its stock price over the last five trading days. Reuters reported 2024-03-28 that The U.S. Food and Drug Administration has extended its review of Applied Therapeutics’ experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday.
Is It Worth Investing in Applied Therapeutics Inc (NASDAQ: APLT) Right Now?
Company’s 36-month beta value is 1.85.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APLT is 74.23M, and currently, short sellers hold a 6.70% ratio of that floaft. The average trading volume of APLT on April 12, 2024 was 1.90M shares.
APLT’s Market Performance
APLT stock saw a decrease of -9.80% in the past week, with a monthly decline of -11.15% and a quarterly a decrease of 99.25%. The volatility ratio for the week is 5.22%, and the volatility levels for the last 30 days are 7.73% for Applied Therapeutics Inc (APLT).. The simple moving average for the past 20 days is -14.60% for APLT’s stock, with a 81.52% simple moving average for the past 200 days.
Analysts’ Opinion of APLT
Many brokerage firms have already submitted their reports for APLT stocks, with RBC Capital Mkts repeating the rating for APLT by listing it as a “Outperform.” The predicted price for APLT in the upcoming period, according to RBC Capital Mkts is $12 based on the research report published on March 26, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see APLT reach a price target of $12. The rating they have provided for APLT stocks is “Outperform” according to the report published on February 22nd, 2024.
Barclays gave a rating of “Equal Weight” to APLT, setting the target price at $7 in the report published on January 04th of the previous year.
APLT Trading at -0.66% from the 50-Day Moving Average
After a stumble in the market that brought APLT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.13% of loss for the given period.
Volatility was left at 7.73%, however, over the last 30 days, the volatility rate increased by 5.22%, as shares sank -12.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +79.80% upper at present.
During the last 5 trading sessions, APLT fell by -9.80%, which changed the moving average for the period of 200-days by +298.51% in comparison to the 20-day moving average, which settled at $6.21. In addition, Applied Therapeutics Inc saw 59.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APLT starting from Shendelman Shoshana, who sale 318,573 shares at the price of $5.39 back on Mar 14 ’24. After this action, Shendelman Shoshana now owns 3,817,814 shares of Applied Therapeutics Inc, valued at $1,717,108 using the latest closing price.
Perfetti Riccardo, the Chief Medical Officer of Applied Therapeutics Inc, sale 110,804 shares at $5.39 during a trade that took place back on Mar 14 ’24, which means that Perfetti Riccardo is holding 1,031,537 shares at $597,234 based on the most recent closing price.
Stock Fundamentals for APLT
Current profitability levels for the company are sitting at:
- -6.46 for the present operating margin
- 0.93 for the gross margin
The net margin for Applied Therapeutics Inc stands at -11.91. The total capital return value is set at 3.95. Equity return is now at value -682.16, with -189.48 for asset returns.
Based on Applied Therapeutics Inc (APLT), the company’s capital structure generated -0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -71.01.
Currently, EBITDA for the company is -64.18 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of 51.67. The receivables turnover for the company is 35.06for trailing twelve months and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.80.
Conclusion
In a nutshell, Applied Therapeutics Inc (APLT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
